<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03659201</url>
  </required_header>
  <id_info>
    <org_study_id>CAEP 0100118PC - Si+Biobetter</org_study_id>
    <nct_id>NCT03659201</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Neosil on Chronic Effluvium</brief_title>
  <official_title>Randomized Clinical Trial, Placebo Controlled and Active Comparator, to Evaluate Efficacy and Safety of Neosil in Chronic Effluvium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Luxbiotech</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of Neosil in the treatment of chronic
      effluvium
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Actual">March 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 4, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hair density</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events recorded during the study</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Chronic Telogen Effluvium</condition>
  <arm_group>
    <arm_group_label>Neosil complete</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will take the tablets, as follow:
3 tablets of Neosil, Oral, per day - during the initial 12 weeks; and
2 tablets of Neosil Oral, per day - during the last 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pantogar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient wil take the tablets, as follow:
3 tablets of Placebo, Oral, per day - during the initial 12 weeks; and
3 tablets of Pantogar, Oral, per day - during the last 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neosil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will take the tablets, as follow:
2 tablets of Neosil Oral, per day - during the 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neosil complete</intervention_name>
    <description>Oral, during 24 weeks.</description>
    <arm_group_label>Neosil complete</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantogar</intervention_name>
    <description>Oral, placebo for 12 weeks and pantogar for 12 weeks.</description>
    <arm_group_label>Pantogar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neosil</intervention_name>
    <description>Oral, during only 12 weeks.</description>
    <arm_group_label>Neosil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who present hair loss for more than 6 months;

          -  Do not use other possible cosmetic or dermatological treatments, during the trial;

          -  Not change the diet during the trial and not be any restrictive diet during this
             period.

        Exclusion Criteria:

          -  Pregnancy or risk of pregnancy and lactating patients;

          -  Use of any products to promote hair growth within the 6 months prior to the Baseline
             Visit;

          -  History of hair transplants;

          -  Current skin disease;

          -  History hypersensitivity to the active ingredients used in the study;

          -  Participation in clinical trial in the year prior to this study;

          -  Known history of non controled systemic disease (diabetes, hypertension, anemia, iron
             deficiency, and others);

          -  Gastric diseases;

          -  Smoker;

          -  History of systemic disease (HIV, non specify autoimmune disease, hepatitis, and
             others).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Caep Centro Avancado de Estudos E Pesquisas Ltda</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13083190</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 3, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

